Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy

Nicholas Marston, Larry Han, Iacopo Olivotto, Sharlene M. Day, Euan A. Ashley, Michelle Michels, Alexandre C. Pereira, Jodie Ingles, Christopher Semsarian, Daniel Jacoby, Steven D. Colan, Joseph W. Rossano, Samuel G. Wittekind, James S. Ware, Sara Saberi, Adam Helms, Carolyn Y. HoEuropean 2021 · DOI

TL;DR

This study reveals that hypertrophic cardiomyopathy (HCM) diagnosed in childhood has distinct clinical characteristics and worse outcomes compared to adult-onset disease. Children with HCM are more likely to have genetic causes related to sarcomeric proteins, face a higher risk of life-threatening arrhythmias, and require advanced heart failure therapies, necessitating tailored clinical management and risk stratification.

What Problem Does This Paper Address?

Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease characterized by unexplained thickening of the left ventricle. While it's known to affect individuals across all ages, the natural history and specific challenges of HCM that begins in childhood have been poorly understood. Previous research often lumped together infant-onset cases (under 1 year) with childhood cases, and sometimes included syndromic causes of heart hypertrophy, obscuring the unique profile of primary childhood-onset HCM. This lack of clarity hinders effective risk stratification and personalized treatment for these young patients. This paper aims to fill that gap by detailing the characteristics and long-term outcomes of a large cohort of children diagnosed with HCM, comparing them to adult counterparts.

Methods

The researchers conducted an observational cohort study using data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a large, international registry of HCM patients. They analyzed data from 7677 patients, stratifying them into three groups based on age at diagnosis: infancy (<1 year), childhood (1-18 years), and adulthood (>18 years).

Key aspects of their methodology include:

  • Cohort Stratification: Patients were divided by age of diagnosis to compare distinct clinical trajectories.
  • Genetic Analysis: Genetic testing data was used to classify patients into "sarcomeric HCM" (due to mutations in genes encoding sarcomere proteins) and "non-sarcomeric HCM." This distinction is crucial as sarcomeric mutations are a common cause of HCM.
  • Outcome Assessment: Composite endpoints were defined to capture major adverse cardiac events, including heart failure (HF), life-threatening ventricular arrhythmias (VA), atrial fibrillation (AF), stroke, and death.
  • Statistical Modeling: Kaplan-Meier analyses were used to estimate event rates over time, and Cox proportional hazards regression models were employed to identify risk predictors and compare outcomes between groups, adjusting for relevant clinical factors.

Datasets

The primary dataset used in this study is the Sarcomeric Human Cardiomyopathy Registry (SHaRe). This is an existing, ongoing, longitudinal registry study that collects data from HCM referral centers across the USA, Brazil, Europe, and Australia. The paper does not introduce a new benchmark dataset.

Key Insights and Ideas

  • Distinct Age Peaks: HCM diagnosis doesn't occur uniformly; there are three notable peaks in age of onset: infancy, adolescence/early adulthood, and middle adulthood. This suggests different underlying disease processes or penetrance patterns.
  • Childhood HCM is Sarcomeric-Dominated: A significant majority (63%) of childhood-onset HCM cases are linked to sarcomeric gene variants, a higher proportion than in infant or adult-onset cases. This genetic predisposition likely drives the more aggressive course seen in this group.
  • Childhood HCM Carries a Higher Burden of Arrhythmias and HF: Patients diagnosed in childhood face a substantially increased risk of life-threatening ventricular arrhythmias and a greater need for advanced heart failure therapies (like transplant or ventricular assist devices) compared to those diagnosed in adulthood.
  • Sarcomeric vs. Non-Sarcomeric Differences Vary by Age: While sarcomeric HCM generally confers a worse prognosis, the specific adverse outcomes differ. In childhood-onset HCM, sarcomeric variants are strongly linked to HF and overall composite events. In adult-onset HCM, sarcomeric variants are more associated with increased risk of all-cause death and AF. This suggests age-dependent modulation of disease expression by genotype.

Key Results

  • Prevalence: Out of 7677 patients, 2.4% were diagnosed in infancy, 14.7% in childhood, and 82.9% in adulthood.
  • Childhood-Onset Outcomes: Childhood-onset HCM patients had an approximate 2% annual event rate for the overall composite endpoint. Ventricular arrhythmias were the most common event in the first decade, while HF and AF became more prevalent by the second decade.
  • Sarcomeric HCM Impact: Sarcomeric HCM was associated with a 63% increased risk of the overall composite outcome and a more than two-fold increased risk of HF in childhood-onset patients.
  • Comparison to Adult-Onset: Childhood-onset HCM was associated with a 36% higher risk of life-threatening ventricular arrhythmias and a two-fold higher likelihood of requiring transplant or ventricular assist device compared to adult-onset HCM.

Limitations and Future Work

The authors acknowledge several limitations:

  • Observational Nature: The study is observational, relying on retrospective data, which can introduce biases like missing data and survival bias.
  • Rarity of Childhood HCM: The relative rarity of childhood-onset HCM limits statistical power to detect subtle differences or identify predictors in smaller subgroups.
  • Potential Survival Bias: Patients who died or experienced major adverse events before referral to a SHaRe site might not be captured, potentially skewing outcomes towards survivors.
  • Competing Risks in Adults: Adult-onset HCM patients often have more comorbidities, increasing the risk of competing events that can complicate outcome analysis.

Future work suggested by the findings includes:

  • Further Characterization of Subgroups: More detailed investigation is needed to better understand the disease etiology and allow for more precise diagnoses and patient stratification across the lifespan.
  • Understanding Genotype-Phenotype Interactions: Further research is required to elucidate the mechanisms behind the age-dependent impact of sarcomeric variants on disease expression.
  • Improved Risk Stratification: The findings provide a foundation for developing more tailored risk stratification tools for children with HCM, focusing on genetic background and specific adverse event profiles.

Summary updated

Abstract

Patients with childhood-onset HCM are more likely to have sarcomeric disease, carry a higher risk of life-threatening ventricular arrythmias, and have greater need for advanced HF therapies. These findings provide insight into the natural history of disease and can help inform clinical risk stratification.
BibTeX
@inproceedings{marston2021clinical,
  author = {Nicholas Marston and Larry Han and Iacopo Olivotto and Sharlene M. Day and Euan A. Ashley and Michelle Michels and Alexandre C. Pereira and Jodie Ingles and Christopher Semsarian and Daniel Jacoby and Steven D. Colan and Joseph W. Rossano and Samuel G. Wittekind and James S. Ware and Sara Saberi and Adam Helms and Carolyn Y. Ho},
  title = {{Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy}},
  booktitle = {European},
  year = {2021},
  doi = {10.1093/eurheartj/ehab148},
}
Figure